Shares of the German prosthetics manufacturer Ottobock experienced a sharp decline on Tuesday, dropping more than 10% following the release of a critical research report by a U.S.-based hedge fund. The report, which initiated a short position on the company, leveled serious allegations against the firm’s majority shareholder and board chair, Hans Georg Näder. Among the claims, the hedge fund accused Näder of siphoning funds from the company to support personal expenditures and alleged that the firm has maintained deeper ties to the Russian market than previously disclosed, potentially facilitating the use of its medical technology in military-related propaganda.

The report further scrutinized the company’s financial structure, specifically highlighting a €1.1 billion payment-in-kind (PIK) loan secured by Näder in early 2024. The hedge fund argued that the compounding interest associated with this debt creates an unsustainable financial burden that places minority shareholders at significant risk. Additionally, the researchers challenged the transparency of the company’s Russian operations, suggesting that the region contributes a much larger share of net income than the figures presented in the firm’s recent initial public offering prospectus.

In response to the accusations, an Ottobock spokesperson stated that the company categorically rejects the claims and the report’s overarching conclusions. While the firm noted that it could not provide a comprehensive rebuttal during its annual general meeting, it indicated that it intends to address the allegations in greater detail following the event. The company, which debuted on the Frankfurt Stock Exchange in October 2025 at an equity valuation of €3.8 billion, has now seen its share price fall by more than 20% since its public listing.

This controversy arrives as the company navigates the challenges of being a publicly traded entity while maintaining a legacy of private control. The allegations regarding Russian business ties specifically reference concerns about brand integrity and potential regulatory exposure, as the firm has previously faced scrutiny over the appearance of its products in media related to Russian veteran care. Ottobock has historically maintained that its operations in the country are strictly limited to civilian medical services.